Skip to main content

Table 8 Assay of the marketed formulations

From: Multivariate optimization and evaluation of quaternary mixture in bulk and co-formulated dosage forms by central composite design

Formulation

Sofosbuvir

Velpatasvir/ledipasvir/daclatasvir

Label claim (mg)

Amount found (mg) (A.M ± SD)

% assay

% RSD

Label claim (mg)

Amount found (mg) (A.M ± SD)

% assay

% RSD

ECLUPSA (SOF + VEL)

400

410.8 ± 1.23

102.7

0.29

100

102.3 ± 0.59

100.2

0.57

HARVONI (SOF + LED)

400

408 ± 1.49

102

0.36

90

89.09 ± 0.25

98.9

0.28

DARVONI (SOF + DAC)

400

409.2 ± 1.56

102.3

0.38

60

61.05 ± 0.45

101.75

0.73

  1. A.M arithmetic mean, SD standard deviation, %RSD relative standard deviation